多系分化应激耐受细胞在组织损伤修复中的研究进展

doi:10.3877/cma.j.issn.2095-1221.2026.05.007

在再生医学领域，开发兼具修复潜力与安全性的"即用型"细胞疗法是核心目标之一。多系分化应激耐受细胞（Muse细胞）是一类内源性间充质干细胞亚群，以阶段特异性胚胎抗原-3阳性、非致瘤性及三胚层分化潜能为主要特征。其修复机制涉及以鞘氨醇-1-磷酸及其受体2 （SIP-SIPR2）轴为核心的损伤组织归巢，通过吞噬凋亡细胞碎片进行的快速原位分化，以及由人类白细胞抗原G表达介导的免疫耐受特性。其安全性基于独特的分子调控网络，通过抑癌因子let-7而非致癌基因维持多能性。临床前研究已证实其在神经、心血管及肝脏等多种损伤模型中的修复作用，而早期临床试验证实其在多种疾病中的良好安全性。尽管Muse细胞的临床转化仍面临细胞来源稀有、规模化生产以及临床前与临床结果差异等挑战，但"无细胞疗法"和激活内源性Muse细胞的策略，是值得关注的未来发展方向。

关键词: 干细胞, 细胞治疗, 再生医学, Muse细胞

A key objective in regenerative medicine is the development of "off-the-shelf" cell therapies that combine reparative potential with a strong safety profile. Multilineage-differentiating stress-enduring (Muse) cells are an endogenous subpopulation of mesenchymal stem cells, primarily characterized by stage-specific embryonic antigen-3 (SSEA-3) positivity, non-tumorigenicity, and the potential for tri-lineage differentiation. Their reparative mechanisms involve homing to damaged tissues mediated by the sphingosine-1-phosphate and its receptor 2 (S1P-S1PR2) axis, rapid in situ differentiation via the phagocytosis of apoptotic cell fragments, and immune tolerance conferred by the expression of human leukocyte antigen-G. The safety profile of Muse cells is predicated on a unique molecular regulatory network that maintains pluripotency through the tumor suppressor let-7, rather than through oncogenes. Preclinical studies have corroborated their reparative efficacy in various injury models, including those of the neurological, cardiovascular, and hepatic systems, while early clinical trials have demonstrated their favorable safety profile across multiple diseases. Although the clinical translation of Muse cells continues to face challenges such as the rarity of cell sources, scalable manufacturing, and discrepancies between preclinical and clinical outcomes, "cell-free" therapies and strategies aimed at activating endogenous Muse cells serve as noteworthy directions for future development.

Key words: Stem cells, Cell therapy, Regenerative medicine, Multilineage-differentiating stress-enduring cells

图1 Muse细胞的提取注：MSCs为间充质干细胞；MACS为磁珠分选；FACS为流式细胞分选

图2 Muse细胞多元化修复机制注：S1P-S1PR2为鞘氨醇-1-磷酸/受体2轴；SDF-1α-CXCR4为基质细胞衍生因子-1α-趋化因子受体4轴；HLA-G为人类白细胞抗原G

表1 Muse细胞主要临床试验汇总

适应证	临床试验注册号	分期	试验设计	患者数量（例）	干预措施	主要结果	参考文献
急性心肌梗死	JapicCTI-183834	Phase 1	开放标签，单臂非对照	3	CL2020：1.5×10⁷ cells，Ⅳ	安全性：未报告与药物相关的药物不良反应、严重不良事件或主要不良心血管事件；疗效（至第12周）：LVEF从40.7提升至52.0 （P < 0.001）；WMSI从1.594降低至1.188	[65]
亚急性缺血性脑卒中	JapicCTI-184103	Phase 2	随机，双盲，安慰剂对照	65	CL2020：1.5 ×10⁷ cells，Ⅳ	安全性：DR发生率：CL2020组28% vs安慰剂组10%；CL2020组报告1例可能相关的4级癫痫持续状态。（3例初期结果）；疗效（mRS ≤ 2，第12周）：CL2020组40.0%vs安慰剂组10.0%；治疗组95%CI下限（21.1%）超过预设阈值（8.7 %）；统计分析（mRS评分偏移分析）：共同比值比（OR）为3.69（95 %CI：0.83 ~ 16.47；P = 0.087）	[26]
脊髓损伤	jRCT1080224764	Phase 2	开放标签，非对照	10	CL2020：1.5×10⁷ cells，Ⅳ	安全性：报告2例SAE，均判定与治疗无关；疗效（ISNCSCI总运动评分自基线变化）：第12周：+13.6分；第52周：+15.4分；所有随访时间点的改善均有统计学意义（P < 0.05）	[66]
肌萎缩侧索硬化	jRCT2063200047	Phase 2	开放标签，非对照	25	CL2020：1.5× 10⁷ cells，Ⅳ （重复给药）	安全性：重复给药方案耐受性良好，未报告与治疗相关的SAE；疗效（ALSFRS-R评分月度下降率）：5例患者中有3例疾病进展减缓或停止	[67]
新生儿缺氧缺血性脑病	NCT04261335（SHIELD试验）	Phase 1	开放标签，剂量递增	11	CL2020：2×10⁵或1×10⁶ cells/kg，Ⅳ	安全性：未报告SAE；唯一可能相关的AE为轻度、一过性γ-GGT升高；疗效（探索性）：67%的患儿在随访时发育商达到正常水平（≥85）	[68，69]
营养不良型大疱性表皮松解症	JapicCTI-184563	Phase 1/2	开放标签，非对照	6	自体或同种异体Muse cells，Ⅳ	安全性：报告1例可能相关的AE （上肢感觉异常），已自愈；疗效：溃疡面积第4周平均减少46.32%，但第12周恢复至基线；疼痛VAS第2周改善（P = 0.003）；瘙痒VAS在第12周和第20周恶化	[70]

表1 Muse细胞主要临床试验汇总

适应证	临床试验注册号	分期	试验设计	患者数量（例）	干预措施	主要结果	参考文献
急性心肌梗死	JapicCTI-183834	Phase 1	开放标签，单臂非对照	3	CL2020：1.5×10⁷ cells，Ⅳ	安全性：未报告与药物相关的药物不良反应、严重不良事件或主要不良心血管事件；疗效（至第12周）：LVEF从40.7提升至52.0 （P < 0.001）；WMSI从1.594降低至1.188	[65]
亚急性缺血性脑卒中	JapicCTI-184103	Phase 2	随机，双盲，安慰剂对照	65	CL2020：1.5 ×10⁷ cells，Ⅳ	安全性：DR发生率：CL2020组28% vs安慰剂组10%；CL2020组报告1例可能相关的4级癫痫持续状态。（3例初期结果）；疗效（mRS ≤ 2，第12周）：CL2020组40.0%vs安慰剂组10.0%；治疗组95%CI下限（21.1%）超过预设阈值（8.7 %）；统计分析（mRS评分偏移分析）：共同比值比（OR）为3.69（95 %CI：0.83 ~ 16.47；P = 0.087）	[26]
脊髓损伤	jRCT1080224764	Phase 2	开放标签，非对照	10	CL2020：1.5×10⁷ cells，Ⅳ	安全性：报告2例SAE，均判定与治疗无关；疗效（ISNCSCI总运动评分自基线变化）：第12周：+13.6分；第52周：+15.4分；所有随访时间点的改善均有统计学意义（P < 0.05）	[66]
肌萎缩侧索硬化	jRCT2063200047	Phase 2	开放标签，非对照	25	CL2020：1.5× 10⁷ cells，Ⅳ （重复给药）	安全性：重复给药方案耐受性良好，未报告与治疗相关的SAE；疗效（ALSFRS-R评分月度下降率）：5例患者中有3例疾病进展减缓或停止	[67]
新生儿缺氧缺血性脑病	NCT04261335（SHIELD试验）	Phase 1	开放标签，剂量递增	11	CL2020：2×10⁵或1×10⁶ cells/kg，Ⅳ	安全性：未报告SAE；唯一可能相关的AE为轻度、一过性γ-GGT升高；疗效（探索性）：67%的患儿在随访时发育商达到正常水平（≥85）	[68，69]
营养不良型大疱性表皮松解症	JapicCTI-184563	Phase 1/2	开放标签，非对照	6	自体或同种异体Muse cells，Ⅳ	安全性：报告1例可能相关的AE （上肢感觉异常），已自愈；疗效：溃疡面积第4周平均减少46.32%，但第12周恢复至基线；疼痛VAS第2周改善（P = 0.003）；瘙痒VAS在第12周和第20周恶化	[70]

1	李晓, 张娇娇, 董友玉. 间充质干细胞在再生医学中的基础研究与临床应用进展[J/OL]. 中华细胞与干细胞杂志（电子版）, 2025, 15(4):229-237.
2	Kirkeby A, Main H, Carpenter M. Pluripotent stem-cell-derived therapies in clinical trial:A 2025 update[J]. Cell Stem Cell, 2025, 32(1):10-37.
3	Shan Y, Zhang M, Tao E, et al. Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges[J]. Signal Transduct Target Ther, 2024, 9(1):242.
4	Ghodasara A, Raza A, Wolfram J, et al. Clinical translation of extracellular vesicles[J]. Adv Healthc Mater, 2023, 12(28):e2301010.
5	Cancedda R, Mastrogiacomo M. The Phoenix of stem cells: pluripotent cells in adult tissues and peripheral blood[J]. Front Bioeng Biotechnol, 2024, 12:1414156.
6	Aprile D, Patrone D, Peluso G, et al. Multipotent/pluripotent stem cell populations in stromal tissues and peripheral blood:exploring diversity, potential, and therapeutic applications[J]. Stem Cell Res Ther, 2024, 15(1):139.
7	Kuroda Y, Kitada M, Wakao S, et al. Unique multipotent cells in adult human mesenchymal cell populations[J]. Proc Natl Acad Sci U S A, 2010, 107(19):8639-8643.
8	Wakao S, Kitada M, Kuroda Y, et al. Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts[J]. Proc Natl Acad Sci U S A, 2011, 108(24):9875-9880.
9	Liu Q, Zhang RZ, Li D, et al. Muse Cells, a new type of pluripotent stem cell derived from human fibroblasts[J]. Cell Reprogram, 2016, 18(2):67-77.
10	Kushida Y, Oguma Y, Abe K, et al. Human post-implantation blastocyst-like characteristics of Muse cells isolated from human umbilical cord[J]. Cell Mol Life Sci, 2024, 81(1):297.
11	Que H, Mai E, Hu Y, et al. Multilineage-differentiating stress-enduring cells:a powerful tool for tissue damage repair[J]. Front Cell Dev Biol, 2024, 12:1380785.
12	黄瑛, 侯田田, 金紫怡. 干细胞治疗国内外监管现状概述及对我国监管体系完善的启示[J/OL]. 中华细胞与干细胞杂志（电子版）, 2025, 15(2):120-126.
13	Ogura F, Wakao S, Kuroda Y, et al. Human adipose tissue possesses a unique population of pluripotent stem cells with nontumorigenic and low telomerase activities:potential implications in regenerative medicine[J]. Stem Cells Dev, 2014, 23(7):717-728.
14	Leng Z, Sun D, Huang Z, et al. Quantitative analysis of SSEA3⁺ cells from human umbilical cord after magnetic sorting[J]. Cell Transplant, 2019, 28(7):907-923.
15	Li H, Wei J, Li M, et al. Biological characteristics of Muse cells derived from MenSCs and their application in acute liver injury and intracerebral hemorrhage diseases[J]. Regen Ther, 2024, 27:48-62.
16	Bi X, Lan Q, Xiao X, et al. Leaf vein scaffolds for three-dimensional culture of PDLSCs-derived Muse cells[J]. J Biotechnol, 2025, 405:275-282.
17	Nitobe Y, Nagaoki T, Kumagai G, et al. Neurotrophic factor secretion and neural differentiation potential of multilineage-differentiating stress-enduring (Muse) cells derived from mouse adipose tissue[J]. Cell Transplant, 2019, 28(9-10):1132-1139.
18	Oguma Y, Kuroda Y, Wakao S, et al. Single-cell RNA sequencing reveals different signatures of mesenchymal stromal cell pluripotent-like and multipotent populations[J]. iScience, 2022, 25(11):105395.
19	Alessio N, Özcan S, Tatsumi K, et al. The secretome of MUSE cells contains factors that may play a role in regulation of stemness, apoptosis and immunomodulation[J]. Cell Cycle, 2017, 16(1):33-44.
20	Heneidi S, Simerman AA, Keller E, et al. Awakened by cellular stress:isolation and characterization of a novel population of pluripotent stem cells derived from human adipose tissue[J]. PLoS One, 2013, 8(6):e64752.
21	Li G, Kitada M, Dezawa M. Hypoxia boosts pluripotent-like muse cell ratio in mesenchymal stromal cells and upregulates the pluripotency gene expression[J]. Sci Rep, 2025, 15(1):31183.
22	Hatabi K, Hirohara Y, Kushida Y, et al. Inhibition of gap junctional intercellular communication upregulates pluripotency gene expression in endogenous pluripotent Muse cells[J]. Cells, 2022, 11(17):2701.
23	Wang L, Xiao L, Zhang RZ, et al. Effects of acrylate/acrylamide polymers on the adhesion, growth and differentiation of Muse cells[J]. Biomed Mater, 2018, 14(1):015003.
24	Chen X, Xu ML, Wang CN, et al. A partition-type tubular scaffold loaded with PDGF-releasing microspheres for spinal cord repair facilitates the directional migration and growth of cells[J]. Neural Regen Res, 2018, 13(7):1231-1240.
25	Lu Z, Ren S, Wang B, et al. 3D dynamic culture of muse cells on a porous gelatin microsphere after magnetic sorting: achieving high purity proliferation[J]. Regen Ther, 2025, 28:402-412.
26	Niizuma K, Osawa SI, Endo H, et al. Randomized placebo-controlled trial of CL2020, an allogenic muse cell-based product, in subacute ischemic stroke[J]. J Cereb Blood Flow Metab, 2023, 43(12):2029-2039.
27	Yamada Y, Wakao S, Kushida Y, et al. S1P-S1PR2 axis mediates homing of muse cells into damaged heart for long-lasting tissue repair and functional recovery after acute myocardial infarction[J]. Circ Res, 2018, 122(8):1069-1083.
28	Shimamura N, Kakuta K, Wang L, et al. Neuro-regeneration therapy using human Muse cells is highly effective in a mouse intracerebral hemorrhage model[J]. Exp Brain Res, 2017, 235(2):565-572.
29	Iseki M, Kushida Y, Wakao S, et al. Muse cells, nontumorigenic pluripotent-like stem cells, have liver regeneration capacity through specific homing and cell replacement in a mouse model of liver fibrosis[J]. Cell Transplant, 2017, 26(5):821-840.
30	Dezawa M. Macrophage- and pluripotent-like reparative Muse cells are unique endogenous stem cells distinct from other somatic stem cells[J]. Front Bioeng Biotechnol, 2025, 13:1553382.
31	Miura T, Kado J, Takiyama H, et al. Stem cell therapy using bone marrow-derived muse cells repairs radiation-induced intestinal injury through their intestine-homing via sphingosine monophosphate-sphingosine monophosphate receptor 2 interaction[J]. Adv Radiat Oncol, 2024, 9(9):101565.
32	Katagiri H, Kushida Y, Nojima M, et al. A distinct subpopulation of bone marrow mesenchymal stem cells, muse cells, directly commit to the replacement of liver components[J]. Am J Transplant, 2016, 16(2):468-483.
33	Wakao S, Oguma Y, Kushida Y, et al. Phagocytosing differentiated cell-fragments is a novel mechanism for controlling somatic stem cell differentiation within a short time frame[J]. Cell Mol Life Sci, 2022, 79(11):542.
34	Takahashi M, Kushida Y, Kuroda Y, et al. Structural reconstruction of mouse acute aortic dissection by intravenously administered human Muse cells without immunosuppression[J]. Commun Med (Lond), 2024, 4(1):174.
35	Fukase M, Sakata N, Kushida Y, et al. Intravenous injection of human multilineage-differentiating stress-enduring cells alleviates mouse severe acute pancreatitis without immunosuppressants[J]. Surg Today, 2022, 52(4):603-615.
36	Minatoguchi S, Fujita Y, Niizuma K, et al. Donor Muse cell treatment without HLA-Matching tests and immunosuppressant treatment[J]. Stem Cells Transl Med, 2024, 13(6):532-545.
37	Li G, Wakao S, Kitada M, et al. Tumor suppressor let-7 acts as a key regulator for pluripotency gene expression in Muse cells[J]. Cell Mol Life Sci, 2024, 81(1):54.
38	Amin M, Kushida Y, Wakao S, et al. Cardiotrophic growth factor-driven induction of human Muse cells into cardiomyocyte-like phenotype[J]. Cell Transplant, 2018, 27(2):285-298.
39	卓馨怡, 祝宇翀, 刘军权. 间充质干细胞制备的纳米囊泡在疾病治疗中的研究进展[J/OL]. 中华细胞与干细胞杂志（电子版）, 2025, 15(1):57-62.
40	Uchida N, Kushida Y, Kitada M, et al. Beneficial effects of systemically administered human muse cells in adriamycin nephropathy[J]. J Am Soc Nephrol, 2017, 28(10):2946-2960.
41	Wang S, Liu Y, Zhang S, et al. Muse cells orchestrating renal repair via macrophage m2 polarization in ischemia-reperfusion injury[J]. Stem Cells Dev, 2025, 34(5-6):136-147.
42	Rajabi A, Bonyadi M. Muse cell-derived exosomes:a hypothesis for a cell-free therapeutic platform in regenerative medicine[J]. Stem Cell Rev Rep, 2025, 21(6):1860-1862.
43	Minatoguchi S, Ando T, Tanaka T, et al. Cardiac rehabilitation with dynamic exercise increases the number of muse cells in the peripheral blood of patients with heart disease[J]. Circ Rep, 2018, 1(1):17-19.
44	Minatoguchi S, Yamada Y, Endo N, et al. Sphingosine-1-Phosphate receptor 2 agonist mobilises endogenous Muse cells to repair damaged myocardial tissue in male rabbits[J]. J Cell Mol Med, 2025, 29(8):e70447.
45	Yamauchi T, Kuroda Y, Morita T, et al. Therapeutic effects of human multilineage-differentiating stress enduring (MUSE) cell transplantation into infarct brain of mice[J]. PLoS One, 2015, 10(3):e0116009.
46	Yamamoto S, Shiraishi K, Kushida Y, et al. Nose-to-brain delivery of human muse cells enhances structural and functional recovery in the murine ischemic stroke model[J]. Sci Rep, 2025, 15(1):16243.
47	Takahashi Y, Kajitani T, Endo T, et al. Intravenous administration of human muse cells ameliorates deficits in a rat model of subacute spinal cord injury[J]. Int J Mol Sci, 2023, 24(19):14603.
48	Yamashita T, Kushida Y, Wakao S, et al. Therapeutic benefit of Muse cells in a mouse model of amyotrophic lateral sclerosis[J]. Sci Rep, 2020, 10(1):17102.
49	Iwabuchi N, Uchida H, Abe T, et al. Multilineage-differentiating stress-enduring cells attenuate the cognitive impairment caused by chronic cerebral hypoperfusion in rats[J]. Exp Neurol, 2025, 387:115185.
50	Suzuki T, Sato Y, Kushida Y, et al. Intravenously delivered multilineage-differentiating stress enduring cells dampen excessive glutamate metabolism and microglial activation in experimental perinatal hypoxic ischemic encephalopathy[J]. J Cereb Blood Flow Metab, 2021, 41(7):1707-1720.
51	Ozuru R, Wakao S, Tsuji T, et al. Rescue from Stx2-Producing E. coli-Associated encephalopathy by intravenous injection of Muse cells in NOD-SCID mice[J]. Mol Ther, 2020, 28(1):100-118.
52	Koyama J, Yamashita S, Kato Y, et al. Intravenously engrafted human multilineage-differentiating stress-enduring (Muse) cells rescue erectile function after rat cavernous nerve injury[J]. BJU Int, 2024, 133(3):332-340.
53	Tanaka T, Nishigaki K, Minatoguchi S, et al. Mobilized muse cells after acute myocardial infarction predict cardiac function and remodeling in the chronic phase[J]. Circ J, 2018, 82(2):561-571.
54	Le NT, Dunleavy MW, Zhou W, et al. Stem cell therapy for myocardial infarction recovery: advances, challenges, and future directions[J]. Biomedicines, 2025, 13(5):1209.
55	Hosoyama K, Wakao S, Kushida Y, et al. Intravenously injected human multilineage-differentiating stress-enduring cells selectively engraft into mouse aortic aneurysms and attenuate dilatation by differentiating into multiple cell types[J]. J Thorac Cardiovasc Surg, 2018, 155(6):2301-2313 e4.
56	Toyoda S, Sakuma M, Ishida K, et al. Accumulation of endogenous Muse cells in the myocardium and its pathophysiological role in patients with fulminant myocarditis[J]. Clin Transl Sci, 2024, 17(11):e70067.
57	Shono Y, Kushida Y, Wakao S, et al. Protection of liver sinusoids by intravenous administration of human Muse cells in a rat extra-small partial liver transplantation model[J]. Am J Transplant, 2021, 21(6):2025-2039.
58	Fujita Y, Komatsu M, Lee SE, et al. Intravenous injection of muse cells as a potential therapeutic approach for epidermolysis bullosa[J]. J Invest Dermatol, 2021, 141(1):198-202.e6.
59	Kinoshita K, Kuno S, Ishimine H, et al. Therapeutic potential of adipose-derived SSEA-3-Positive muse cells for treating diabetic skin ulcers[J]. Stem Cells Transl Med, 2015, 4(2):146-155.
60	Mineda K, Feng J, Ishimine H, et al. Therapeutic potential of human adipose-derived stem/stromal cell microspheroids prepared by three-dimensional culture in non-cross-linked hyaluronic acid gel[J]. Stem Cells Transl Med, 2015, 4(12):1511-1522.
61	Guo Y, Xue Y, Wang P, et al. Muse cell spheroids have therapeutic effect on corneal scarring wound in mice and tree shrews[J]. Sci Transl Med, 2020, 12(562):eaaw1120.
62	Sun D, Yang L, Cao H, et al. Study of the protective effect on damaged intestinal epithelial cells of rat multilineage-differentiating stress-enduring (Muse) cells[J]. Cell Biol Int, 2020, 44(2):549-559.
63	Tian T, Zhang RZ, Yang YH, et al. Muse cells derived from dermal tissues can differentiate into melanocytes[J]. Cell Reprogram, 2017, 19(2):116-122.
64	Fouad AM, Gabr MM, Abdelhady EK, et al. In vitro differentiation of human multilineage differentiating stress-enduring (Muse) cells into insulin producing cells[J]. J Genet Eng Biotechnol, 2018, 16(2):433-440.
65	Noda T, Nishigaki K, Minatoguchi S. Safety and efficacy of human muse cell-based product for acute myocardial infarction in a first-in-human trial[J]. Circ J, 2020, 84(7):1189-1192.
66	Koda M, Imagama S, Nakashima H, et al. Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury:a clinical trial[J]. Stem Cell Res Ther, 2024, 15(1):259.
67	Yamashita T, Nakano Y, Sasaki R, et al. Safety and clinical effects of a muse cell-based product in patients with amyotrophic lateral sclerosis: results of a phase 2 clinical trial[J]. Cell Transplant, 2023, 32:9636897231214370.
68	Sato Y, Shimizu S, Ueda K, et al. Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial)[J]. Stem Cells Transl Med, 2024, 13(11):1053-1066.
69	Matsuyama N, Shimizu S, Ueda K, et al. Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial):a clinical trial protocol open-label, non-randomised, dose-escalation trial[J]. BMJ Open, 2022, 12(4): e057073.
70	Fujita Y, Nohara T, Takashima S, et al. Intravenous allogeneic multilineage-differentiating stress-enduring cells in adults with dystrophic epidermolysis bullosa:a phase 1/2 open-label study[J]. J Eur Acad Dermatol Venereol, 2021, 35(8):e528-e31.
71	Dezawa M. Comparison of MSCs and Muse cells:the possible use for healthspan optimization[J]. Biogerontology, 2025, 26(4):139.
72	Galipeau J, Sensébé L. Mesenchymal stromal cells:Clinical challenges and therapeutic opportunities[J]. Cell Stem Cell, 2018, 22(6):824-833.
73	Salvadori M, Cesari N, Murgia A, et al. Dissecting the pharmacodynamics and pharmacokinetics of mscs to overcome limitations in their clinical translation[J]. Mol Ther Methods Clin Dev, 2019, 14:1-15.

[1]	王博, 李全, 胡静, 李洋洋, 从嘉男, 海日罕, 曹胜军. 丝素蛋白修饰的羊脱细胞真皮基质复合人脂肪间充质干细胞膜片对小鼠全层皮肤缺损创面的影响及其机制[J/OL]. 中华损伤与修复杂志(电子版), 2026, 21(04): 289-298.
[2]	张传凯, 曾梦, 向凯, 任明星, 杨生. 刺激响应性生物材料在组织修复与再生中的微环境调控策略[J/OL]. 中华口腔医学研究杂志(电子版), 2026, 20(04): 262-272.
[3]	张文青, 强茹月, 裴丹丹, 张辉. 不同杨氏模量聚丙烯酰胺水凝胶模型的构建及其对小鼠骨髓间充质干细胞行为的影响[J/OL]. 中华口腔医学研究杂志(电子版), 2026, 20(04): 304-310.
[4]	许成裘, 李亮, 严聪. 疝与腹壁外科修补材料的发展：从人工假体到组织工程支架[J/OL]. 中华疝和腹壁外科杂志(电子版), 2026, 20(04): 477-480.
[5]	李文芳, 董孟炜, 杨万彭, 巴特, 南楠, 刘杨, 郝慧琴. 关节腔注射脂肪间充质干细胞对碘乙酸钠诱导大鼠急性软骨损伤的抗炎及组织学修复作用[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(05): 266-277.
[6]	成津, 郭建明. 间充质干细胞治疗糖尿病足溃疡的研究现状与进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(05): 278-284.
[7]	郑宏, 孙碧红, 苑倩, 杨培, 刘阳. 毛囊干细胞的研究进展与应用探索[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(05): 285-291.
[8]	姚雪, 曹佩琪, 杨林花. 造血干细胞移植在骨髓增生异常综合征治疗中的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(05): 292-297.
[9]	王琼, 刘媛, 巩婷, 刘奕晞, 谭震, 但刚, 胡丽娜, 郭郑斌, 张睿. 高原低氧诱导红细胞增多的细胞机制研究进展及干细胞治疗潜力[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(05): 298-304.
[10]	刘丽丽, 高笑微, 张志华. 大块组织块法分离培养人脐带间充质干细胞的可行性研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(04): 193-200.
[11]	闫鸣琪, 向秋玲. 诱导多能干细胞分化的心肌细胞在遗传性原发性心律失常综合征模型中的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(04): 233-239.
[12]	赵娟, 田峻. 脂肪源性间充质干细胞向骨髓腔归巢促进骨组织修复的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(04): 240-245.
[13]	刘欣贤, 陈柏煜, 魏玲玲. 细胞治疗糖尿病的临床突破与进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(04): 246-254.
[14]	姜海珍, 江煜焓, 张丹, 陈晨晨. 骨髓间充质干细胞外泌体调控TLR4/NF-κB信号通路缓解小鼠子宫内膜异位症研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(03): 140-149.
[15]	齐洪武, 李晶晶. 干细胞治疗动脉瘤性蛛网膜下腔出血的研究进展[J/OL]. 中华脑科疾病与康复杂志(电子版), 2026, 16(03): 170-176.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Advances in multilineage-differentiating stress-enduring cells for tissue injury repair

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Advances in multilineage-differentiating stress-enduring cells for tissue injury repair